| Date Filed | Type | Description |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 05/16/2023 |
4
| Grais Linda (Director) has filed a Form 4 on Corvus Pharmaceuticals, Inc.|
Txns:
| Bought 10,000 shares
@ $2.45, valued at
$24.5k
|
|
| 05/09/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/24/2023 |
8-K
| Quarterly results |
| 04/03/2023 |
4
| MILLER RICHARD A MD (President and CEO) has filed a Form 4 on Corvus Pharmaceuticals, Inc.|
Txns:
| Granted 800,000 options to buy
@ $0.91, valued at
$728k
|
|
| 04/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/28/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 0% stake in Corvus Pharmaceuticals, Inc. |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/30/2023 |
SC 13G/A
| INTEGRATED CORE STRATEGIES LLC reports a 4.1% stake in CORVUS PHARMACEUTICALS, INC. |
| 12/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/15/2022 |
4
| LEA LEIV (CFO) has filed a Form 4 on Corvus Pharmaceuticals, Inc.|
Txns:
| Bought 30,000 shares
@ $0.7425, valued at
$22.3k
Bought 4,000 shares
@ $0.841, valued at
$3.4k
|
|
| 12/15/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/03/2022 |
8-K/A
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/28/2022 |
8-K
| Quarterly results |
| 09/28/2022 |
4
| MILLER RICHARD A MD (President and CEO) has filed a Form 4 on Corvus Pharmaceuticals, Inc.|
Txns:
| Bought 25,000 shares
@ $0.7628, valued at
$19.1k
|
|
| 09/20/2022 |
4
| MILLER RICHARD A MD (President and CEO) has filed a Form 4 on Corvus Pharmaceuticals, Inc.|
Txns:
| Bought 12,300 shares
@ $0.8101, valued at
$10k
Bought 2,700 shares
@ $0.82, valued at
$2.2k
Bought 5,000 shares
@ $0.815, valued at
$4.1k
|
|
| 08/15/2022 |
4
| LEA LEIV (CFO) has filed a Form 4 on Corvus Pharmaceuticals, Inc.|
Txns:
| Granted 160,000 options to buy
@ $0.965, valued at
$154.4k
|
|
| 08/15/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/15/2022 |
4
| Jones William Benton (See Remarks) has filed a Form 4 on Corvus Pharmaceuticals, Inc.|
Txns:
| Granted 160,000 options to buy
@ $0.965, valued at
$154.4k
|
|
| 08/15/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/15/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|